Heart Failure in Ischemic Stroke: Relevance for Acute Care and Outcome

Stroke. 2019 Nov;50(11):3051-3056. doi: 10.1161/STROKEAHA.119.026139. Epub 2019 Sep 27.

Abstract

Background and Purpose- Heart failure (HF) in patients with acute ischemic stroke constitutes the source of various detrimental pathophysiologic mechanisms including prothrombotic and proinflammatory states, worsening of cerebral tissue oxygenation, and hemodynamic impairment. In addition, HF might affect the safety and efficacy of the acute recanalization stroke therapies. Methods- Patients treated with intravenous recombinant tissue-type plasminogen activator or mechanical recanalization at a universitary stroke center were included into a prospective registry. Patients received cardiological evaluation, including echocardiography, during acute care. Functional outcome was assessed after 90 days by structured telephone interviews. Safety and efficacy of intravenous thrombolysis and mechanical thrombectomy were investigated among patients with HF and compared with patients with normal cardiac function after propensity score matching. Results- One thousand two hundred nine patients were included. HF was present in 378 patients (31%) and an independent predictor of unfavorable functional outcome. Recanalization rates were equal among patients with HF after intravenous thrombolysis and after mechanical recanalization or combined treatment. The rate of secondary intracranial hemorrhage was not different (7% versus 8%; P=0.909 after thrombolysis and 15% versus 20%, P=0.364 after mechanical recanalization or combined therapy). Early mortality within 48 hours after admission was equal (<1.5% in both groups). Conclusions- In this real-world cohort of patients with stroke, HF was an independent predictor of unfavorable functional long-term outcome, while the safety and efficacy of intravenous thrombolysis and mechanical recanalization appeared unaffected.

Keywords: heart failure; humans; registries; telephone; thrombectomy.

Publication types

  • Clinical Trial
  • Observational Study

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Brain Ischemia* / complications
  • Brain Ischemia* / mortality
  • Brain Ischemia* / therapy
  • Cerebral Revascularization*
  • Disease-Free Survival
  • Female
  • Heart Failure* / etiology
  • Heart Failure* / mortality
  • Heart Failure* / therapy
  • Humans
  • Intracranial Hemorrhages* / etiology
  • Intracranial Hemorrhages* / mortality
  • Intracranial Hemorrhages* / therapy
  • Male
  • Mechanical Thrombolysis*
  • Prospective Studies
  • Registries*
  • Stroke* / complications
  • Stroke* / mortality
  • Stroke* / therapy
  • Survival Rate
  • Time Factors
  • Tissue Plasminogen Activator* / administration & dosage
  • Tissue Plasminogen Activator* / adverse effects

Substances

  • Tissue Plasminogen Activator